GlobeNewswire by notified

European Energy A/S: Notice to convene ordinary general meeting

Share

Company announcement 7/2024 (28.02.2024)

The Board of Directors of the Company hereby convenes an ordinary general meeting of the Company, to be held on:

Thursday 14 March 2024 at 09:30 CET at the address of the Company, Gyngemose Parkvej 50, 2860 Søborg, Denmark and electronically on Teams

Agenda:

  1. Election of Chair of the Annual General Meeting.
  2. Report on the activities of the Company.
  3. Presentation of the annual report with the auditors’ report for approval and discharge of the Board of Directors and the Executive Board.
  4. Resolution on the appropriation of profit or treatment of loss according to the approved annual report.
  5. Election of members to the Board of Directors.
  6. Decision regarding remuneration to the Board of Directors for the financial year 2024.
  7. Amendments to the article of association.
  8. Election of Auditor(s).
  9. AOB.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ledende medarbejderes og disses nærtståendes transaktioner17.4.2024 08:42:03 CEST | pressemeddelelse

Indberetning nr. 5 / 2024 Indberetning og offentliggørelse om aktiebesiddelser hos Jyske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug. For yderligere detaljer henvises til de vedhæftede skemaer. Vedhæftede filer Appendiks – Lars Mørch - 16.04.2024Appendiks – Niels Erik Jakobsen - 16.04.2024Appendiks – Per Skovhus - 16.04.2024Appendiks – Peter Schleidt - 16.04.2024

Transactions by persons discharging managerial responsibilities and persons closely associated with them17.4.2024 08:42:03 CEST | Press release

Disclosure 5 / 2024 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in compliance with the EU Commission Market Abuse Regulation. Further details are included in the attachments. Attachments Appendix – Lars Mørch - 16.04.2024Appendix – Niels Erik Jakobsen - 16.04.2024Appendix – Per Skovhus - 16.04.2024Appendix – Peter Schleidt - 16.04.2024

Cortus Energy AB deltar på Nordbex projektlansering för satsning på koldioxidnegativ elproduktion i Nybro kommun den 18 april17.4.2024 08:00:00 CEST | Pressemelding

Stockholm, den 17 april 2024 PRESSMEDDELANDE Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) deltar på projektlansering om koldioxidnegativ elproduktion, tillsammans med samarbetsparter Nordbex AB (”Nordbex”). Nordbex presenterar sin satsning och ambitionen att göra Nybro kommun koldioxidnegativ innan 2030 genom ett koldioxidnegativt kraftverk med Cortus Energys förgasningsteknologi, WoodRoll®. Under projektlanseringen kommer den svenska projektutvecklaren Nordbex presentera miljardsatsningen på koldioxidnegativ elproduktion som görs i Nybro kommun. Det första koldioxidnegativa kraftverket ska byggas av Nordbex, där Cortus WoodRoll®-förgasningsteknologi har en central roll till följd av den rena syngasen som produceras. Nordbex kraftverk kommer att generera 135 GWh ren energi och samla in 200 000 ton koldioxid från atmosfären varje år. Projektlanseringen inleds med en presentation av Nordbex, vilken går att följa live från och med kl 16:00 den 18 april på följande länk https://www.y

Norsk Hydro: Reminder - Invitation to Hydro's first quarter results 202417.4.2024 08:00:00 CEST | Press release

Hydro's first quarter results 2024 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on Wednesday, April 24, 2024. The quarterly report and presentation will be available on hydro.com at the same time. President and CEO Hilde Merete Aasheim and Executive Vice President, Corporate Development & acting CFO Trond Olaf Christophersen will host a webcast in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters. To join the webcast and ask questions, register your details in the webcast page. Once registered, you will receive a separate email confirming your registration. The webcast is powered by Livestorm. We advise that you investigate in advance if your company has any restrictions using this platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS17.4.2024 08:00:00 CEST | Press release

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024 Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treat

HiddenA line styled icon from Orion Icon Library.Eye